IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.
Now we know why SAA directors were happy to extend the PUSU deadline. This is a far better outcome for every possible reason, hence the market reaction. So glad I had patience to wait this out. Even ADVT share price has been boosted this morning…
I will admit that I’m disappointed by this. If SAA were the company I thought they were, they’d have told Vin and ADvT to take a hike. IMO there is absolutely no way of integrating these two companies without significantly reducing the sum of the parts.
However, it means that I will have a clear exit strategy: if the bid is approved by the SAA board I’ll be accepting the offer & selling out since it will require a price in the region of c.£3 per share, which is where I thought SAA would be in a year or two. If the offer is rejected, I will hold for the LT
GL all & dyor
Suspension prevents us from buying the suitor, but I agree that a failure of the deal will most likely result in a price recovery there.
Also, “The impact on culture” is an oblique reference to the likelihood that there will be a mass exodus of SAA talent. In fact I’m surprised that they’ve agreed a month’s extension. There are a lot of people (and possibly some clients) who will be unnerved by this process. New business drive will also be compromised...
For me, this is the key paragraph in today’s RNS:
On 28 January 2022 certain of the Independent Directors together with a representative of their financial advisers met with Vin Murria and Marwyn Investment Management ("Marwyn"), the two largest shareholders of AdvT. At the meeting, those Independent Directors reiterated the concerns previously raised in the Company's announcements of 7 and 24 January 2022, including the continued undervaluation of the Company; the strategy of the enlarged AdvT group and, in particular, the lack of clarity over the deliverability of, and execution risk associated with, their proposed 'digital-led M&A' strategy; the impact on culture; how AdvT intends to ensure the retention and appropriate incentivisation of M&C Saatchi 's key management and employees; and the valuation of AdvT's ordinary shares.
I mentioned the point about key SAA executives in a previous post. I really cannot see the deal going through.
Seems like the market hasn’t been convinced of the value of this buyout: $1.5m up front, followed by a further $1.5m in earn outs over 3 years. With Annualized revenue of $1.2m, running costs of $500k, and zero net tangible assets, it doesn’t sound convincing really.
The ROIB team need to demonstrate their worth very quickly - ideally before or when the Full Year’s results are announced on 23 March
I feel that ADVT will have to increase their offer substantially if they hope to succeed with their bid. But before they do that, they will have to ensure that they have the majority of the SAA board in agreement with their proposal.
It’s complex of course, as it always is, but if VM thinks that her senior management experience with Tech or IT companies has any correlation with senior management within the advertising business, she needs to think again. SAA’s key clients have selected the company as much for the executives that run their accounts, and the creatives that produce the work, as they have for the pedigree of the Saatchi brand. None of them will have signed long term let alone permanent contracts with SAA, and most contracts will stipulate that a change in key personnel (names will be named) will trigger the possibility of an account review. Terms offered to the SAA Directors will have to be extremely generous, just for starters.
Not that anyone reading this will necessarily believe me, but I spent nearly 20 years in the advertising industry, hence my post. I also hold shares in ADVT, so I find myself somewhat conflicted - although tbh I invested in THAT company because I expected their investments to be within her area of expertise rather than advertising. My investment in SAA was based on a recovery play from my entry point at 125p following the accounting debacle and the departure of board directors responsible for it.
Yes, I sold a little too early in the day (121.4) back on 10 November, but happy to have done so since I now have the opportunity to buy back in 10% below my exit price. It will be interesting to see what emerges from the scientists about this latest variant, since ITV is currently anchored in the UK market as far as SP movements go. We may well see sub-100 prices again if there’s sufficient fear about a new, more virulent wave of Covid.
And no, I’m not a new account for Bournemouth Tom London, but it would serve a number of people on here to at least consider an alternative point of view. Or are these boards meant to be echo chambers?
It's probable that there will be a retrace after all the day-traders take profits, and lots more like me have taken the opportunity to hit the exit with a reasonable profit. All the good news in the Q3 Trading Statement is now in the price, so it's time to bank a profit and keep this one on the Watchlist
GLA
If you consider how long we have been waiting for final sign-off of the Amapa deal, I feel that it would be a grave error to be shouting from the rooftops that our deal is nearly done. PR’ing a “nearly done deal” is more harmful than helpful.
Then think about the cost of recruiting either an in-house specialist, or a PR Agency that is knowledgeable & connected in our field. They don’t come cheap, and they won’t have been doing a great deal to earn their pay over the last few years. Some on here might even have been complaining about the excessive cost, and the need to liquidate even more of our other assets to pay it.
Only IMO, it’s likely that Kiran has a PR firm in mind for the time when he actually has something concrete to announce. In the meantime it’s the broker, WH Ireland, that should be trying to generate interest and coverage.
It’s been disconcerting to see such a significant drop in share price over the past few days. Certainly leads to a suspicion of a poor update on Pollinex Quattro trial results as mentioned by Padd1. There are some AIM shares that are notoriously leaky, but I hadn’t considered this to be one of them.... until now, since the volumes are significant too.
However, on a positive note, it seems that we have significant price support at ~33p which still puts us way ahead of historic prices. I’ve decided to wait this out.
Yes, I’m in on the same basis jimjam
I still think the balls of steel brigade will end up with a nice polish. Instead of being an even-money shot priced at 10-1, we’re now looking at an odds-on runner priced a little bigger IMO - DYOR etc etc
Allergy Therapeutics announces details of secondary endpoints
from successful VLP Peanut 001 trial
- Ex-vivo data for VLP Peanut support a beneficial efficacy profile
- Demonstrates reduced ability to trigger immune cells associated with allergic reactions
- Findings complement primary outcome of hypoallergic potential of VLP Peanut and provide confidence in upcoming VLP Peanut first in-human Phase I PROTECT study
13 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, today announces the secondary endpoint results from an ex-vivo biomarker study VLP001 which evaluated the Group's novel virus-like particle (VLP) based peanut allergy vaccine candidate ("VLP Peanut").
The secondary endpoint results demonstrated a reduced IgE binding capacity to B cells of VLP Peanut suggesting a promising safety profile with reduced potency to induce allergic reactions.
Further, the results provide a strong indication for the products' efficacy potential, promoting a class switch from the allergic Th2 pathway to the more tolerogenic Th1 pathway;
· Lower ability to elicit Th2 and Tfh (T follicular helper) cells
· Strong ability to promote IFN- ? and Th1 cells
· Promotion of selected regulatory B cell subsets
Previously announced primary endpoint data demonstrated a significant 24-fold reduction in basophil activation and histamine release compared to exposure to the major allergen Ara h2, these results provide strong confidence in the beneficial immunologic mode of action of VLP Peanut.
The VLP001 study took place at Imperial College London and evaluated the Group's short-course VLP Peanut vaccine candidate. In combination with the primary outcome data, these secondary endpoint results are encouraging and provide strong support for the human translation of the pre-clinical results and strong confidence in the data to be generated in the planned Phase I PROTECT study. The data also provide important information to establish the starting dose for PROTECT, which is expected to commence in Q1 2022.
The Group's Chief Executive Officer, Manuel Llobet, will host a webinar on Friday 17th September, when he will be joined by Dr. Mohamed Shamji of Imperial College London, who will provide an overview of the results of the VLP001 study. In addition, Dr. Matthew Heath, Principal Scientist at Allergy Therapeutics will be discussing the scientific background of the vaccine candidate and the concept of using VLPs to address peanut allergy. Those wishing to view the webinar are encouraged to visit the Group website
https://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=15182551
This is the RNS as published on AGY’s website
small trader - sorry it’s taken awhile to respond.
You’re right. I stand corrected. My prior understanding of earnouts was that they have variable terms, and are therefore difficult to nail down. However, I’m now assuming that the best forecasts are included as debt even if they are variable & subject to adjustment.
In any event, your interpretation was clearly correct. Apologies for doubting.